The Impact of Enhanced Access to Modern Antineoplastic Drugs for Breast Cancer Treatment on Mortality and Economic Development

Speaker(s)

Avxentyev NA1, Frolov M2, Makarov A3, Makarova Y4
1Financial Research Institute and Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia. Pharmaceutical Analytics Middle East, Ras al Khaimah, United Arab Emirates, 2Volgograd state medical university, Volgograd Medical Scientific Center, Volgograd, VGG, Russia, 3Pharmaceutical Analytics Middle East, Ras al Khaimah, Ras al Khaimah, United Arab Emirates, 4Financial Research Institute, Moscow, MOW, Russia

Presentation Documents

OBJECTIVES: Enhanced funding and price reductions improve access to modern antineoplastic drugs in most developed countries. Some of these drugs have shown overall survival benefits compared to standard therapy, suggesting that expanding their accessibility reduces mortality and supports economic growth. This study aims to quantitatively evaluate these effects for medications used in breast cancer (BC) treatment in Russia.

METHODS: The analysis spanned from 2019 to 2024, with 2018 as the base year. We identified high-cost drugs registered in Russia for BC treatment that have shown overall survival benefits in clinical trials. Analyzing their procurement between 2018 and 2021, we estimated the number of patients who received these medications. Procurements assumed to remain constant from 2021 until 2024. The number of prevented BC deaths was estimated considering the enhanced accessibility and overall survival benefits of these drugs. The economic impact resulting from the reduced mortality was evaluated using the theory of human capital, incorporating data on age and gender employment distribution in Russia.

RESULTS: Trastuzumab, pertuzumab, trastuzumab emtansine and CDK4/6 inhibitors meet inclusion criteria for this study. From 2018 to 2021 the number of patients annually receiving these medications doubled to 17.1 thousand. This allowed to prevent 724 deaths for the period of 2019-2021. By the end of the period 2,459 lives could be saved, including 664 in 2024, which is a 3% reduction in mortality from breast cancer compared to the baseline level.

Reduced mortality leads to production increase of US$11 million during 2019 - 2024, while additional expenditures for the drug procurement are estimated at US$1.4 billion.

CONCLUSIONS: Expanding the availability of modern drugs for BC treatment reduces mortality, however GDP increase resulting from this improvement is lower than the additional expenses required for drug procurement.

Code

MSR144

Topic

Methodological & Statistical Research

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology